Hot Medical Companies To Watch For 2015


Wheat futures rose for a second day on signs of improved demand for U.S. exports after prices touched a 14-month low. Soybeans and corn also advanced. Bloomberg reports wheat inspected for export jumped 56% to 46.024 million bushels in the week ended Sept. 12 from a year earlier, the U.S. Department of Agriculture said Sept. 16. Sales since June 1 rose 38% to 602 million bushels as of Sept. 5 from the same period a year earlier, the agency said. Average U.S. cash prices fell Sept. 6 to the lowest since June 2012, down 20% this year, the Minneapolis Grain Exchange said. As always, use stops and keep an eye on the 10-handle rule. Don’t forget to catch MrTopStep on The Closing Print. We report directly from the SPX pits, wrapping up the day and positioning for trade tomorrow. OptionsProfits can be followed on Twitter at twitter.com/OptionsProfits MrTopStep can be followed on Twitter at twitter.com/MrTopStep For LIVE futures chat, more information on the 10-handle rule and futures educational content CLICK HERE FOR A SEVEN-DAY FREE TRIAL.

Hot Medical Companies To Watch For 2015: Provectus Pharmaceuticals Inc (PVCT)


Provectus Pharmaceuticals, Inc., incorporated on May 1, 1978, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atop ic dermatitis, a type of eczema. All of the Company’s prescription drug candidates are in either the pre-clinical or clinical trial stage.


PV-10

As of December 31, 2011, the Company is developing PV-10, a sterile injectible form of rose bengal disodium (Rose Bengal), for direct injection into tumors. Its PV-10 is retained in diseased or damaged tissue but dissipates from healthy tissue. The Company had conducted Phase I and Phase IIstudies of PV-10 for the treatment of metastatic melanoma, and Phase I studies of PV-10 for the treatment of liver and breast cancers.

PH-10

The Company’s prescription drug candidate PH-10 is an aqueous hydrogel formulation of Rose Bengal for topical administration to the skin. The Company is developing PH-10 for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. In August 2011, the Company completed follow-up of all Phase IIc patients.


Over-th e-Counter Pharmaceuticals

The Company had desi! gnated its subsidiary that holds its OTC products, GloveAid and Pure-ific, Pure-Stick, Pure N Clear as non-core. The Company’s GloveAid is a hand cream with both antiperspirant and antibacterial properties, for the comfort of users’ hands during and after the wearing of disposable gloves. Its Pure-ific line of products includes two quick-drying sprays, Pure-ific and Pure-ific Kids, that immediately kill up to 99.9% of germs on skin and prevent regrowth for six hours. Pure-ific products prevent the spread of germs and thus complement its other OTC products designed to treat irritated skin or skin conditions, such as acne, eczema, dandruff and fungal infections. Its Pure-ific sprays have been designed with convenience in mind and are targeted towards mothers, travelers, and anyone concerned about the spread of sickness-causing germs.


The Company’s acne products Pure-Stick and Pure N Clear work by decreasing the production of fats, oils and sweat that create an environment conducive to unchecked growth of bacteria. Secondly, the products also act to reduce the number bacteria already present. The Pure-Stick and Pure N Clear are applied topically to affected areas there are no safety concerns with healthy skin.

Advisors’ Opinion:

  • [By Luke Jacobi]

    Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.38 percent to $3.01, letting out some air after the company’s opening on the NYSE Friday.

  • [By Jake L’Ecuyer]

    Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.02 percent to $3.01, letting out some air after the company’s opening on the NYSE Friday.

Hot Medical Companies To Watch For 2015: CryoLife Inc (CRY)

CryoLife, Inc. (CryoLife,), incorporated in January 19,1984, is a biological medical device company. The Company preserves and distributes human tissues for transplantation and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve (CryoValve SGPV) and the CryoPatch SG pulmonary cardiac patch tissue (CryoPatch SG), both processed using CryoLife’s SynerGraft technology. The Company operates in two segments: preservation services and medical devices segment. The preservation services segment includes services revenues from the preservation of cardiac and vascular tissues during the year ended December 31, 2011. The medical devices segment includes revenues from product sales of BioGlue, BioFoam, PerClot, HemoStase and revascularization technologies, as well as sales of other medical devices. CryoLife’s surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam) and PerClot, an absorbable powdered hemostat. In May 2011, it acquired Cardiogenesis Corporation. In May 2012, the Company acquired Hemosphere, Inc. Hemosphere develops and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. In February 2014, CryoLife Inc announced the establishment of CryoLife Asia Pacific Pte. Ltd.


CryoLife distributes preserved human cardiac and vascular tissues to implanting institutions throughout the United States (U.S), Canada and Europe. CryoLife processes and preserves cardiac and vascular tissues using processing and freezing techniques, or cryopreservation. The Company’s preservation process involves the recovery of tissue from deceased human donors by tissue banks and organ procurement organizations (OTPOs), the delivery, of such tissue to the Company, the s! creening, dissection, disinfection, processing, and preservation of the tissue by the Company, and the storage and shipment of the preserved tissue.


The human heart valves and cardiac patch tissues preserved by the Company are used in cardiac reconstruction and heart valve replacement surgeries. The Company preserves human aortic and pulmonary heart valves for implantation by cardiac surgeons. In addition, the Company preserves human cardiac patches for surgeons. The Company preserves human cardiac patches in three primarily anatomic configurations: pulmonary hemi-artery, pulmonary trunk and pulmonary branch. As of December 31, 2011, CryoLife shipped approximately 77,600 heart valves and cardiac patch tissues, including approximately 3,000 shipments during 2011.


The human vascular tissues preserved by the Company, including the CryoVein and CryoArtery, are used to treat a variety of vascular reconstructions, such as peripheral bypass, hemodialysi s access and aortic infections. The Company preserves small diameter human saphenous vein conduits (3 millimeter to 6 millimeter) for use in peripheral vascular reconstructions. The Company also preserves femoral veins and arteries and aortoiliac arteries for bypass, hemodialysis access, or reconstruction within infected surgical areas. As of December 31, 2011, the Company shipped approximately 66,100 human vascular tissues, including approximately 4,500 shipments during 2011.


CryoLife’s product BioGlue, designed for cardiac, vascular, pulmonary, and general surgical applications, is a polymer based on bovine blood protein and an agent for cross-linking proteins. CryoLife distributes BioGlue throughout the United States and approximately 75 other countries. CryoLife distributes BioGlue for repair of soft tissues under conformite Europeene Mark Product Certification (CE Mark). CryoLife distributes BioGlue in Japan for use in the repair of aortic dissections.

CryoLife’s product, BioFoam, is a protein hydr! ogel biom! aterial with an expansion agent, which generates a mixed-cell foam. The foam creates a mechanical barrier to decrease blood flow and develops pores for the blood to enter, leading to cellular aggregation and enhanced hemostasis. CryoLife distributes BioFoam under CE Mark certification.


CryoLife’s product, PerClot, is an absorbable, powdered hemostatic agent used in surgery. PerClot particles have a molecular structure that absorbs water from blood, creating a high concentration of platelets, red blood cells, and coagulation proteins at the bleeding site, which accelerates the physiologic clotting cascade. PerClot is readily dissolved by saline irrigation and is totally absorbed within several days. PerClot is available in one gram, three gram and five gram sizes with a 100 millimeter or 200 millimeter applicator tip. PerClot Laparoscopic is available in one gram and three gram sizes with a 380 millimeter applicator tip.


The Company competes with S t. Jude Medical, Inc., Medtronic, Inc., Edwards Life Sciences, Inc., Neovasc, Inc., LifeNet Health, Inc. W.L. Gore & Associates’ Propaten, C.R. Bard, Inc., Hancock Jaffe Laboratories, Inc., Maquet, Inc., CorMatrix Cardiovascular, Inc., Baxter International, Inc., Johnson & Johnson Company, Covidien Ltd, NeoMend, Inc., Pfizer, Inc., Orthovita, Inc., King Pharmaceuticals, Inc., Ethicon, Inc., ZymoGenetics, Inc. and Nycomed.

Advisors’ Opinion:

  • [By Eric Volkman]

    CryoLife (NYSE: CRY  ) is putting some zip into its shares with a dividend boost. The company has declared a fresh quarterly distribution of $0.0275 per share, to be paid on June 21 to shareholders of record as of June 14. This marks the company’s first-ever dividend increase — the new amount is 10% higher than its three prior (and only) payouts, each of which totaled $0.025.

Hot Medical Companies To Watch For 2015: Stemline Therapeutics Inc (STML)


Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline’s StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.


SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bul k of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.


SL-401 – An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancer s, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.


SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.


StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and follo wing CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.


The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.


Advisors’ Opinion:

  • [By Jay Silverman]

    Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird’s case, the price that had actually opened up as an IPO, even though it’s above its IPO price.

  • [By David Zeiler]

    3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.

  • [By Keith Speights]

    Best-performing biotech IPO
    Stemline Therapeutics  (NASDAQ: STML  ) has only traded publicly this year, but what a year it’s been. The stock’s performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.

Hot Medical Companies To Watch For 2015: Galectin Therapeutics Inc (GALT)

Galectin Therapeutics Inc., formerly Pro-Pharmaceuticals, Inc., incorporated on January 26, 2001, is a development-stage company. The Company is engaged in drug development to create therapies for cancer and fibrotic disease. As of December 31, 2011, the Company has two compounds in development, one is to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from different natural starting materials, both possessing the property, which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, the Company’s product candidate for cancer therapy, is a linear polysaccharide polymer consisted of mannose and galactose that has a defined chemical structure and is derived from a plant source. GR-MD-02, the Company’s product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a polysaccharide polymer possessing both linear and globul ar structures, which also is derived from a plant source.


GM-CT-01 has in development for the therapy of colorectal cancer and is in a Phase I/II clinical trial as a combination therapy with a tumor vaccine in patients with advanced melanoma. Based on the completed Phase I and partially completed Phase II clinical trials, the Company is exploring two additional potential indicia for the use of GM-CT-01 in combination with cancer chemotherapy. There are two additional pathways for the development of GM-CT-01 for use in treatment of cancer. GM-CT-01 was found to be generally safe when studied in a Phase I clinical trial in end-stage cancer patients with multiple tumor types alone and in combination with 5-Fluorouracil (5-FU), which is an Food and Drug Administration (FDA)-approved chemotherapy used for treatment of various types of cancer.


Advisors’ Opinion:

  • [By Roberto Pedone]

     

    Galectin Therapeutics (GALT) offers drug research and development to create new therapies for fibrotic disease and cancer. This stock closed up 9.6% to $12.06 in Monday’s trading session.

     

    Monday’s Volume: 674,000

    Three-Month Average Volume: 222,171

    Volume % Change: 149%

     

    Shares of GALT jumped higher on Monday after Ascendiant initiated coverage on the stock with a buy recommendation.

     

     


    From a technical perspective, GALT spiked sharply higher here with strong upside volume. This stock has been uptrending for the last three months, with shares ripping higher from its low of $3.95 to its recent high of $13.21. During that move, shares of GALT have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GALT within range of triggering a near-term breakout trade. That trade will hit if GALT manages to take out Monday’s high of $12.44 and then once it clears its 52-week high at $13.21 with high volume.


     

    Traders should now look for long-biased trades in GALT as long as it’s trending above some near-term support levels at $11 or at $10 and then once it sustains a move or close above those breakout levels with volume that hits near or above 222,171 shares. If that breakout hits soon, then GALT will set up to enter new 52-week-high territory above $13.21, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $16.

     

Hot Medical Companies To Watch For 2015: NanoViricides Inc (NNVC)


NanoViricides, Inc., incorporated on April 1, 2005, is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company’s drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. As of June 30, 2012, the Company had six drug development programs: Oral FluCideTM, against all Influenzas; a Piggy-back version of Flucide for hospitalized patien ts; nanoviricide eye drops against adenoviral EKC and herpes keratitis; HIVCide – I against HIV/AIDS; HerpeCide – I skin cream formulation for herpes cold sores and genital warts, and DengueCide, a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS). As of June 30, 2012, it had engaged in organizational activities, sourcing compounds and materials, developing novel compounds and nanomaterials, and experimentation with studies on cell cultures and animals. In September 2011, NanoViricides Inc’s Inno-Haven LLC acquired a light industrial building.


The Company’s product development programs are divided into three sectors: commercially important diseases, neglected tropical diseases (NTD’s) and biosecurity/biodefense, and advanced technologies. The Company has collaborations with KARD Scientific, Inc., MA. and Southern Research Institute, AL for influenza viruse! s; National (Central) Institute of Hygiene and Epidemiology (NIHE) (Vietnam), for H5N1 avian flu; The Long Island Jewish Medical System, Feinstein Institute of Medical Research (LIJMS), NY and TheVac, LLC. for viral diseases of the eye (adenoviruses, herpesviruses – epidemic kerato-conjunctivitis (EKC), Herpes Keratitis); TheVac, LLC and Northeastern Ohio Medical University (NEOMED) for herpes virus infections; University of California at Berkeley for dengue hemorrhagic fever viruses; Center for Disease Control and Prevention (CDC) and National (Central) Institute of Hygiene and Epidemiology for rabies virus. The Company has developed lead drug candidates against a number of viral diseases.


The Company had consolidated all of its influenza drug programs into a single pan-influenza FluCide program. It is developing a single drug for all influenzas, whether pandemic, epidemic, seasonal, novel, emerging, human, swine, or avian. It is developing a nanoviricide agai nst adenoviral EKC. The nanoviricide eye drug candidate is formulated as simple eye drops. It is developing an anti-HSV nanoviricide skin cream formulation for direct application to the lesions. It has designed the anti-HIV nanoviricides using rational drug design principles. The ligands it has designed in the case of HIV-1 are thought to be broadly neutralizing. In-silico modeling indicates that its ligands dock to the conserved CD4 binding site of gp120 of HIV-1. The Company is working on developing anti-Dengue therapeutics. Dengue is an important NTD. Its RabiCide program has resulted in candidates that have enabled survival of 20% to 30% of infected animals after disease has set in, using a particular animal model.

The Company competes with Roche, Glaxo SmithKline, BioCryst Pharmaceuticals, Inc., Gilead, Bristol-Myers Squibb Company (BMS), Roche, Boehringer Ingelheim, Merck & Co., Inc. (Merck), Valeant, Schering, Pharmassett, Vertex, Intermune, Achillion and Novartis.

Advisors’ Opinion:

  • [By Roberto Pedone]

    One under-$10 nano-biopharmaceutical player that’s starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.

    If you take a look at the chart for Nanoviricides, you’ll notice that this stock has recently formed a double bottom chart pattern at $4.55 to $4.52 a share. Following that bottom, shares of NNVC have now started to uptrend and move within range of triggering a big breakout trade. That trade will hit if NNVC manages to take out the upper-end of its recent sideways trading chart pattern, which has seen NNVC trend between $4.55 and $5.74 a share.

    Traders should now look for long-biased trades in NNVC if it manages to break out above some near-term overhead resistance levels at Friday’s high of $4.94 a share to its 50-day moving average of $5.28 a share, and then once it takes out some more key overhead resistance levels at $5.72 to $5.74 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 234,994 shares. If that breakout triggers soon, then NNVC will set up to re-test or possibly take out its next major overhead resistance levels at $6.50 to its 52-week high at $7.59 a share.

    Traders can look to buy NNVC off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.55 to $4.52 a share. One can also buy NNVC off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.